BioSpace News Archive

LIVMOR, Inc., a leading digital health solutions company, announced today that the Company received FDA 510(k) clearance for the LIVMOR Halo™ AF Detection System,

NEXGEL, Inc., an innovative company developing ultra-gentle, high-water content E-beam hydrogels with a focus on the consumer over-the-counter, Rx, medical device and cosmetic markets, announced the creation of a wholly owned subsidiary, NEXGEL Rx, to purpose their all-natural hydrogels as a drug and cell delivery system.

The 17-time chart-topping, multi-platinum duo Florida Georgia Line received the coveted Randy Owen “Angels Among Us” award during a livestream for St. Jude Children’s Research Hospital®.

IT4Innovations National Supercomputing Center gains faster performance and targeted AI capabilities for data-intensive research using HPE Apollo systems featuring NVIDIA A100 GPUs

Invacare Corporation announces that it will release its financial results for the third quarter ended September 30, 2020, after the market closes on Thursday, October 29, 2020.

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced preliminary third quarter 2020 revenue and provided a business update.

Owens & Minor, Inc. plans to release financial results for the third quarter of 2020 on Monday, November 2, 2020, after trading ends on the New York Stock Exchange.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via webcast on Monday, November 9, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:45 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Nov

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced the publication of a manuscript in Blood Advances, a journal of the American Society of Hematology.

Acquisition expands Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s promising preclinical SARM1 programs for axonal degeneration [15-October-2020] INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-he